MXPA99002272A - Compositions and methods for the treatment of atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoi - Google Patents

Abstract

The compositions and methods for the treatment of atopic dermatitis, angioedema, urticaria, allergic rhinitis and others of these disorders are described herein. The compositions contain therapeutically effective amounts of antihistamines such as, for example, loratadine and glucocorticoids, for example betamethasone. , for such treatment

Description

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATOPIC DERMATITIS, ANGIOEDEMA AND OTHER DISORDERS USING ANTIHISTAMINES AND GLUCOCORTICOIDS FIELD OF THE INVENTION The present invention relates generally to compositions and methods for treating atopic dermatitis, angioedema, urticaria, allergic rhinitis and other disorders. Specifically, compositions containing therapeutically effective amounts of antihistamines such as, for example, loratadine, and glucocorticoids, such as, for example, betamethasone, are described for such treatment.

BACKGROUND OF THE INVENTION _ Atopic dermatitis is a chronic superficial inflammation of the skin that produces pruritus, usually found in individuals with a history of allergic disorders. (The Merck Manual of Diagnosis and Therapy, D.

Holvey ed., Published by Merck & Co., Inc., Rahway, New Jersey, (1972) 1460). Angioedema and urticaria are local rashes and erythema in the dermis that may be due to causes such as, for example, drug allergies, insect bites and the like, and Ibid, page 241. Atopic dermatitis is usually managed by application of ointments or Topical corticosteroid pastes, itching is usually relieved by antihistamines, often in large doses. The drugs used initially, in general, can become ineffective and should be replaced. Acute urticaria is often managed by oral antihistamines; Corticosteroid treatments occasionally may be necessary, particularly when associated with angioedema. Topical corticosteroids are usually not of value. Products containing a combination of a steroid and an antihistamine are known and available. For example, a product containing chlorpheniramine maleate and parametasone which is available under the trademark DILARMINE® from Roche Pharmaceuticals, Nutley, New Jersey. However, antihistamines in such products are commonly sedatives. There may be situations where sedating antihistamines are not acceptable. It would be desirable to find pharmaceutical compositions and effective methods of treatment for diseases such as atopic dermatitis, angioedema, urticaria, allergic and seasonal rhinitis, allergies to food and medicines, allergic contact dermatitis, seborrheic dermatitis [sic], neurodermatitis, allergic asthma, manifestations allergic eye symptoms such as conjunctivitis and iridocyclitis, allergic reaction to bites and insect bites and other such disorders.

It would be especially desirable to find compositions and methods of treatment for such diseases using an effective amount of a combination of one or more antihistamines, which are substantially non-sedating, with one or more glucocorticoids. Further, such a combination composition and methods of treatment wherein the selected non-sedating antihistamine (s) and glucocorticoid (s) are safe and with a low potential for systemic toxicity would be further desirable. Other desires, objects and advantages of the present invention will be clear to those skilled in the art from the description and accompanying claims.

DESCRIPTION OF THE INVENTION The aforementioned purposes and objectives are obtained by means of the present invention which, in one embodiment, provides pharmaceutical compositions for the treatment of diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, allergies to food and medication, allergic contact dermatitis, seborrheic dermatitis [sic], neurodermatitis, allergic asthma, allergic ocular manifestations, such as conjunctivitis and iridocyclitis, allergic reactions to the bites and bites of insects and other disorders. The composition contains in combination: (i) a therapeutically effective amount of one or more antihistamines substantially non-sedating or pharmaceutically acceptable salts or solvates of such antihistamine (s) and (ii) a therapeutically effective amount of one or more glucocorticoids or a suitable derivative thereof. The present invention further describes a method for the treatment of the aforementioned diseases in a mammalian organism in need of this treatment. Such treatment comprises administering a pharmaceutical composition described above. The antihistamines used in the practice of the present invention correspond to the general formula I: Formula I wherein X represents a halogen atom or a hydrogen atom; and Y represents hydrogen, -COORi or -S02R2, wherein Ri represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aryl group, or a ring substituted or unsubstituted heterocyclic; and R2 represents a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group. The term "substituted" refers to an appropriate substitution with such fractions as, for example, alkyl, aryl, aralkyl, alkylaryl, cycloalkyl, heterocyclic, halogen, ester, amide, ether, carbonyl, sulfonyl, and the like. I comprise optical isomers and mixtures thereof, racemic mixtures, enol forms and other such modifications The preferred compounds belonging to formula I are those in which X is a halogen atom or a hydrogen atom, and Y is a hydrogen or -COORi, where Ri was defined above.The most particularly preferred compounds of this class are where X is Cl and Ri is carboethoxy (the compound being commonly known as loratadine) and wherein X is Cl and Ri is hydrogen (being the compound commonly known as descarboethoxylaratadine or desloratadine or DCL) The compounds of the formula I can be prepared according to the processes known in the art, for example it, those described in US Patent Nos. 3,326,924 and 4,282,233. DCL is described, for example, in U.S. Patent No. 4,659,716 and is a metabolic derivative of loratadine. Glucocorticoids generally belong to a class of steroid hormones that are synthesized by the adrenal cortex in vertebrates and have anti-inflammatory activity. Many are well known. Glucocorticoids useful in the practice of the present invention include, for example, prednisolone, prednisone, betamethasone, dexamethasone, fluorometalone, medrisone, triamcinolone, hydrocortisone, prednicarbate, deflazacort, halometasone, thixocortol, prednilidine (21-diethylaminoacetate), prednival, parametasone, methylprednisolone, meprednisone, mazipredone, isoflupredone, halopredone acetate, halcinonide, formocorthal, flurandrenolide, fluprednisolone, fluprednin acetate, fluperolone acetate, fluocortolone, butyl fluocortin, fluocinonide, fluocinolone acetonide, flunisolode, flumetasone, fludrocorstisone, enoxolone, difluprednate, diflucortolone, diacetate diflorasone, deoximetasone, desonido, cortivazol, corticosterone, cortisone, cloprednol, clocortolone, clobetasone, clobetasol, chloroprednisone, cafestol, budesonide, beclomethasone, amcinonide, alopregnano acetonide, alclometasone, 21-acetoxipregnenolone, tralonido, diflurasone acetate, desacilcortivazole, bu Sound; oxyatanone deacycortivazole, and the like. Some of these compounds are known glucocorticoids and many are described in The Merck Index, 20th Ed., Merck & Co., Inc., Rahway, New Jersey (1996). Preferred glucocorticoids include betamethasone, prednisolone, predisone, flumethasone, and hydrocortisone. The most preferred is betamethasone. Loratadine has been studied extensively for its antihistaminic effects and is considered to be a safe antihistamine as a Hi antagonist. It is also considered to be an antihistamine without clinically significant sedative effects. It has also been proven to be effective and safe for the treatment of severe respiratory diseases and dermatological allergies. Betamethasone (formula II) is a synthetic fluorinated hydrocortisone derivative and has anti-inflammatory properties. Betamethasone has been Formula II has been widely used in the clinic, as well as a reference corticosteroid in various clinical tests. The description can be found in, for example, A. Munck et al., * Physiological Functions of Glucocorticoids in Stress and their Relation to Pharmacological Actions ", Endocr. Rev., vol. 5 (1984), 25-44. A combination of an antihistamine such as loratadine and a glucocorticoid such as betamethasone has now been found to be a highly effective medicament for treating allergic diseases and those listed above without having a sedative effect. As already mentioned, the present invention, in general, describes novel pharmaceutical compositions comprising, a substantially non-sedating antihistamine and glucocorticoids. Additionally, other optional ingredients may be present such as, for example, pharmaceutically acceptable carriers. Still additional ingredients may also be present, especially depending on the form of administration of the pharmaceutical composition, as detailed below. Antihistamine or its pharmacologically acceptable salt or solvate are generally present in the composition at about 2-20 milligrams per dose, preferably at about 2-10 milligrams and commonly at about 3-7 milligrams. The glucocorticoid is generally present in the composition at about 0.02-1 milligram per dose, preferably at about 0.02-0.8 milligrams and commonly at about 0.03-0.5 milligrams. Preferably the weight ratio of the glucocorticoid and antihistamine is in the range between about 1: 100 and 1:10. As noted above, a pharmaceutically acceptable carrier (including diluents, excipients or carrier materials) may also be present in the composition. The carrier is suitably selected with respect to the proposed administration form, ie, oral tablets, capsules (with solid charge material, semi-solid charge material or liquid loading material), powder for reconstitution, oral gels, elixirs, solutions, syrups, suspensions, and the like, and which are consistent with pharmaceutically conventional practices. For example, for oral administration, in the form of tablets or capsules, the active ingredients (ie, antihistamine and glucocorticoid) can be combined with any non-toxic pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, ethyl alcohol (liquid forms) and the like. In addition, when needed or desired, suitable binders, lubricants, disintegrating agents, disinfecting agents, and colorants can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethyl cellulose, polyethylene glycol and waxes. Suitable lubricants that may be mentioned for use in these dosage forms include, for example, boric acid, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include starch, methyl cellulose, guar gum and the like. The disinfectants include benzalkonium chloride and the like. Sweetening and flavoring agents and preservatives as well as other ingredients, such as, for example, croscarmellose sodium, may be included as appropriate. In another embodiment, the present invention describes a method for preparing a composition for use in the treatment of diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, allergies to food and drugs, allergic contact dermatitis, seborrhoeic dermatitis [sic], neurodermatitis, allergic asthma, allergic ocular manifestations such as conjunctivitis and iridocyclitis, allergic reactions to bites and insect bites and other disorders, with the composition comprising a therapeutically effective amount of one or more substantially non-sedating antihistamines, or a pharmaceutically acceptable salt or solvate of this antihistamine, and one or more therapeutically effective glucocorticoids, optionally in combination with a pharmaceutically acceptable carrier. In still another embodiment, the present invention describes a method of administering an effective treatment for diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, dermatitis seborrheic [sic], neurodermatitis, allergic asthma, allergic ocular manifestations such as conjunctivitis and iridocyclitis, allergic reactions to bites and insect bites and other disorders, administration, consists of administering a pharmaceutical composition described above. The pharmaceutical compositions of the present invention can be administered depending on the age of the patient, sex, weight and the severity of the condition to be treated. Generally, the oral dosage form for the human containing the antihistamine and the carrier can be administered once or twice a day. In another embodiment, this invention describes a method for the treatment of diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoeic dermatitis [sic], neurodermatitis, allergic asthma, allergic ocular manifestations such as conjunctivitis and iridocyclitis, allergic reactions to bites and insect bites and other disorders in a mammalian organisms in need of such treatment, such treatment comprises administering a therapeutically effective amount of one or more antihistamines substantially not sedatives, or a pharmaceutically acceptable salt or solvate of such antihistamine, and one or more therapeutically effective glucocorticoids optionally in combination with a pharmaceutically acceptable carrier. In addition, the composition of the present invention can be formulated in sustained release form to provide the rate of controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects. Suitable dosage forms for sustained release include coated tablets containing varying disintegration rate layers or controlled release polymer matrices impregnated with the active and molded components in the form of tablets or capsules containing such impregnated or encapsulated porous polymer matrices. The dosage form refers to the composition containing the antihistamine, the glucocorticoid and optionally a carrier formulated in a delivery system, i.e., tablet, capsule, oral gel, powder for reconstitution or suspension in association with inactive ingredients. Capsule- refers to a special container or wrap made of methyl cellulose, polyvinyl alcohols or denatured gelatins or starch for storing or containing the compositions containing the active ingredients and optionally the carrier. Hard-walled capsules are commonly made from mixtures of bone gelatin and pig skin with a relatively high gel concentration. The capsule itself may contain small bleaching quantities, opacifying agents, plasticizers and preservers. Tablet- refers to a molded or compressed solid dosage form containing the active ingredients with suitable diluents. The tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or by compaction. Oral gels refer to active ingredients and carriers dispersed or solubilized in a semi-solid hydrophilic matrix. Powders for reconstitution refers to mixtures of powders containing the active ingredients and suitable carriers and diluents that can be suspended in water or juice.

Diluent- refers to substances that usually make up the largest portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potatoes; and celluloses such as microcrystalline cellulose. The amount of diluent in the composition may be in the range from about 2 to about 98% by weight of the total composition. Disintegrants - refers to materials added to the composition to help break it into pieces (disintegrate) and release the drugs. Suitable disintegrants include starches; modified starches * soluble in cold water "such as sodium carboxymethyl starch; natural and synthetic gums such as carob, karaya gum (sterculiaceous), guar, tragacanth and agar; cellulose derivatives such as methyl cellulose and sodium carboxymethyl cellulose; celluloses microcrystallines and cross-linked microcrystalline celluloses such as croscarmellose sodium, alginates such as alginic acid and sodium alginate, clays such as bentonites, and effervescent mixtures.The amount of disintegrant in the composition may be in the range from about 1 to about 15% by weight of the composition.

Binders refer to substances that agglutinate or "stick" the powders together and make them cohesive to form granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose; starches derived from wheat, corn, rice and potatoes; natural gums such as acacia, gelatin, and tragacanth; seaweed derivatives, such as alginic acid, sodium alginate and calcium ammonium alginate; cellulosic materials such as cellulose, methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose; polyvinyl pyrrolidone; and inorganics such as aluminum magnesium silicate. The amount of binder in the composition may be in the range from about 2 to about 98% by weight of the composition. Lubricant- refers to a substance added to the dosage form to allow the tablet, granules, etc., after they have been compressed, to be released from the mold or matrix reducing friction or wear. Suitable lubricants include metal stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid, waxes of high melting point; and water-soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and d-leucine. Lubricants are usually added in the last step before compression, since they must be present on the surfaces of the granules and between these and the parts of the tablet press. The amount of lubricant in the composition can be in the range from about 0.05 to about 5% by weight of the composition. Slides - materials that prevent compaction and improve the flow characteristics of the granulations, so much that the fluid is smooth and uniform. Suitable glidants include silicon dioxide and talc. The amount of glidants in the composition can be in the range from about 0.1% to about 5% by weight of the total composition. Coloring agents - excipients that provide coloration to the composition or dosage form. Such excipients may include food grade colorants and food grade colorants adsorbed on a suitable adsorbent such as clay or aluminum oxide. The amount of the coloring agent can vary from about 0.1 to about 5% by weight of the composition. Bioavailability- refers to the rate and degree to which the active ingredient of the therapeutic drug or fraction * is absorbed in the systemic circulation Id of a dosage form administered as compared to a standard or control, as well as topical bioavailability. Conventional methods for preparing tablets are known. Such methods include dry methods such as direct compression and granulation compression produced by compaction, or wet methods or other special procedures. The phrase "therapeutically effective amount" means the amount of the active ingredients that provide a therapeutic benefit in the treatment or management of the aforementioned diseases by the composition of the present invention The magnitude of the prophylactic or therapeutic dose of the active ingredients in the acute or chronic management of the disease or target state may vary with the severity of the condition to be treated and route of administration.The dose, and perhaps the frequency of the dose, may also vary according to age, body weight and individual patient response The ranges of adequate total daily doses can be quickly determined by those skilled in the art.The dose can be administered in individual doses or divided doses, orally, topically, transdermally, or locally by inhalation. recommends that children, patients older than 65 years, and those with renal or hep function atica damaged initially receive low doses, and that they then be qualified based on individual response (s) or level (s) in blood. In addition, it should be noted that the clinician or attending physician will know how and when to adjust, interrupt or terminate the therapy taking into account the patient's individual response. Any suitable route of administration can be employed to provide the patient with an effective dose of active ingredients according to the methods of the present invention. Some such routes are, for example, oral, intra oral, rectal, parenteral, epiucutaneous, transdermal, subcutaneous, intramuscular, intranasal, sublingual, intradural, intraocular, intrarespiratory, oral or nasal inhalation and the like. Oral administration is preferred. The term "pharmaceutically acceptable salt" refers to a salt prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids or bases or organic acids or bases, Example of these inorganic acids are hydrochloric, hydrobromic, hydroiodic, sulfuric and phosphoric acids. Suitable organic acids can be selected, for example, from aliphatic, aromatic, carboxylic, and sulfonic acid classes, examples of which are formic, acetic, propionic, succinic, glycolic, glucuronic, maleic, furoic, glutamic, benzoic. , anthranilic, salicylic, phenylacetic, mandelic, embonic (pamico), methanesulfonic, ethanesulfonic, pantothenic, benzenesulfonic, stearic, sulfanilic, algic, and galacturonic Examples of such inorganic bases include metal salts made of aluminum, calcium, lithium, magnesium, sodium potassium and zinc, the appropriate organic bases can be for example, of N, N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumain, (N-methylgulcaine), lysine and procaine. A similar meaning is given to the term "pharmaceutically acceptable solvate" which, however, includes a solvent, water and the like as a solvation medium.As already stated, the dosage forms include, tablets, pills, dispersions, suspensions, solutions, capsules, troches, syrups, elixirs, gels, powders, magmas, pills, ointments, creams, pastes, plasters, lotions, discs, suppositories, nasal or oral spray, aerosols and the like, due to the ease of administration, tablets and Capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed.If desired, the tablets can be covered by standard aqueous or non-aqueous techniques.Another preferred dosage form is as a liquid or solution, which contains the active ingredients together with any optional ingredients or ingredients, in a pharmaceutically acceptable carrier that is preferably liquid. Pharmaceutical compositions for use in the methods of the present invention may be prepared by any of the methods of the pharmacy, but all methods include the step or steps of bringing into association the active ingredients and any optional ingredients or ingredients, the carrier and Similar. As generally stated, the compositions are prepared by uniformly and intimately admixing the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing, in a suitable machine, the active ingredients in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active agent or dispersant. The molded tablets can be prepared by molding, in a suitable machine, a mixture of the powdered composition moistened with an inert liquid diluent.

An example of a composition containing loratadine and metabetasone for a tablet, and the preparation of a tablet by a compression molding process can be illustrated as in the following Table I: The aforementioned ingredients can be mixed in any suitable order and converted into a tablet by the appropriate methods such as, for example, the methods mentioned at the beginning. Thus, in one example, betamethasone (0.25 mg) and loratadine (5 mg) were premixed with a portion (70 mg) of FASTFLO ® lactose (available from Foremost Farm USA, Baraboo, Wisconsin). The mixture was then passed through a Quadro CoMill® mill (a sieve mill available from Quadro, Waterloo, Ontario, Canada) equipped with 20 mesh screen. The remaining portion of lactose FASTFLO ® (71.75 mg) and croscarmellose sodium (2) mg) were then added and mixed. Magnesium stearate (1 mg) was then mixed and incorporated well. The mixture was then compressed in a rotary tablet press to make tablets. A tablet weighing approximately 150 milligrams can be prepared with the aforementioned composition. Otherwise, a tablet can be prepared by a wet granulation method. An example of a composition containing loratadine and betamethasone for a tablet and the preparation of a tablet by a wet granulation process can be illustrated as in the following Table II. In Table II, AVICEL PH3001® is a microcrystalline cellulose, available from EMC Corporation Pharmaceutical Division, City of Industry, California; Kollidon VA 64® is a modified polyvinylpyrrolidone available from BASF Mexicana S.A de C.V. Av, from Deportes C.P., México, D.F .; Kollidon CL® is another modified polyvinylpyrrolidone available from BASF Mexicana S.A de C.V. Av, from Deportes C.P., México, D.F.

Table II In the illustrative process, in a suitable container, sufficient alcohol was taken to dissolve loratadine (5 mg), betamethasone (0.25 mg) and Kollidon VA64® (3 mg) and all three ingredients were dissolved. In a separate mixer, cellulose (84.65 mg) and Kollidon CL® (7 mg) were mixed for approximately 15 minutes and this mixture was then mixed and granulated with the alcohol solution and mixed to form a uniform granulate. The granulate was then spread on trays and dried in an oven until a moisture level of 1.5-2.5% was obtained. The granulate was then passed through a 25 mesh screen, loaded in a mixer and mixed well with magnesium stearate (0.1 mg) for approximately 2 minutes. This mixture was then compressed into tablets using a 4 inch deep round tablet press and concave punches. Various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are proposed to be within the scope of the invention and appended claims. In addition, although the above illustrated examples are prepared using loratadine and betamethasone as the active ingredients, it would not be considered as limiting the scope of the invention in any way; another suitable substitution of the active ingredients can be made using the aforementioned list of suitable compounds. Modifications of the active ingredients and other ingredients as well as the appropriate processes should also be considered within the scope of the invention, description and appended claims.

Claims (37)

1. A pharmaceutical composition for the treatment of atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, allergies to food and medicines, allergic contact dermatitis, seborrheic dermatitis [sic], neurodermatitis, allergic asthma, allergic ocular manifestations such as conjunctivitis and iridocyclitis, Allergic reactions to stings and insect bites, this composition comprises: (i) a therapeutically effective amount of one or more substantially non-sedating antihistamines or a pharmaceutically acceptable salt or solvate thereof; and (ii) a therapeutically effective amount of one or more glucocorticoids.

2. The composition of claim 1 for the treatment of atopic dermatitis.

3. The composition of claim 1 for the treatment of angioedema.

4. The composition of claim 1, wherein said antihistamine corresponds to the general formula: wherein X represents a halogen atom or a hydrogen atom; and Y represents hydrogen, -COORi or -SO, R2, wherein Ri represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic ring, and R2 represents a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group as well as optical isomers and mixtures of said antihistamine, the substituents being Ci-Ce alkyl, aralkyl, alkylaryl, aryl and cycloalkyl.

The composition of claim 4, wherein X is halogen and Y is hydrogen or -COORi, wherein Ri is the same as in claim 4.

The composition of claim 5, wherein X is Cl and Y is -COOC2H5, being the antihistamine known as loratadine.

7. The composition of claim 5, wherein X is Cl and Y is hydrogen, the antihistamine being known as desloratadine.

The composition of claim 1, wherein said glucocorticoid is selected from the group consisting of prednisolone, prednisone, betamethasone, dexamethasone, fluorometalone, medrisone, triamcinolone, hydrocortisone, prednicarbate, deflazacort, halometasone, tixocortol, prednilidine (21-diethylaminoacetate) , prednival, parametasone, methylprednisolone, meprednisone, mazipredone, isoflupredone, halopredone acetate, halcinonide, formoco.rtal, flurandrenolide, fluprednisolone, fluprednin acetate, fluperolone acetate, fluocortolone, butyl fluocortin, fluocinonide, fluocinolone acetonide, flunisolode, flumetasone, fludrocorstisone , enoxolone, difluprednate, diflucortolone, diflorasone diacetate, desoximetasone, desonido, cortivazol, corticosterone, cortisone, cloprednol, clocortolone, clobetasone, clobetasol, chloroprednisone, cafestol, budesonide, beclomethasone, amcinonide, alloregnane acetonide, alclometasone, 21-acetoxipregnenolone, tralonido, acetate diflurasone, desacilcortivazole, budesonide, desacylcortivazole oxetanone and mixtures thereof.

9. The composition of claim 8, wherein said glucocorticoid is betamethasone.

10. The composition of claim 1 additionally contains one or more ingredients selected from the group consisting of a pharmaceutically acceptable carrier, binder, lubricant, de-inking agent, disinfectant, coloring agents, flavoring agent and preservative.

The composition of claim 10, wherein said additional ingredient is a pharmaceutically acceptable carrier.

The composition of claim 11, wherein said pharmaceutically acceptable carrier is selected from the group consisting of lactose, sucrose, sugar, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, ethyl alcohol and mixtures thereof .

The composition of claim 12, wherein said carrier is lactose.

The composition of claim 12, wherein said carrier is magnesium stearate.

15. The composition of claim 1, further comprising croscarmellose sodium.

16. The composition of claim 1, being present in the form of a tablet.

17. The composition of claim 1, being present in the form of a capsule.

18. The composition of claim 1, being present in the form of a liquid.

19. The composition of claim 18, wherein said liquid is a solution of the composition in a suitable solvent.

The composition of claim 16, wherein the tablet is prepared by compression.

The composition of claim 16, wherein the tablet is prepared by granulation. -----

22. The composition of claim 1, wherein the antihistamine is present in amounts in the range of 2-20 milligrams per dose.

23. The composition of claim 1, wherein the antihistamine is present in amounts in the range of 2-10 milligrams per dose.

The composition of claim 1, wherein the antihistamine is present in amounts of about 3-7 milligrams per dose.

The composition of claim 1, wherein the glucocorticoid is present at approximately 0.02-1 milligrams per dose.

26. The composition of claim 1, wherein the glucocorticoid is present at approximately 0.02-0.8 milligrams per dose.

27. The composition of claim 1, wherein the glucocorticoid is present at approximately 0.03-0.5 milligrams per dose.

28. The composition of claim 1, wherein the glucocorticoid and the antihistamine are present in a respective weight ratio in the range between 1: 100 and 1:10.

29. A method for the treatment of atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, allergies to food and medicines, allergic contact dermatitis, seborrheic dermatitis [sic], neurodermatitis, allergic asthma, allergic ocular manifestations such as conjunctivitis and iridocyclitis, Allergic reactions to bites and insect bites, in a mammalian organism in need of this treatment, the method consists in administering to the organism a composition containing: (i) a therapeutically effective amount of one or more substantially non-sedating antihistamines or a salt or pharmaceutically acceptable solvate thereof; and (ii) a therapeutically effective amount of one or more glucocorticoids.

30. The method of claim 29, wherein the antihistamine corresponds to the general formula: where X represents a halogen atom or a hydrogen atom; and Y represents hydrogen, -COORi or S02R2, wherein Ri represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aryl group, or a heterocyclic ring substituted or unsubstituted, and R2 represents a substituted or unsubstituted cycloalkyl group or a substituted or unsubstituted aryl group as well as optical isomers and mixtures of said antihistamine 31.

The method of claim 30, wherein X is Cl and Y is -COOC2H5, being the antihistamine known as loratadine.

The method of claim 29, wherein the glucocorticoid is selected from the group consisting of prednisolone, prednisone, betamethasone, dexamethasone, fluorometalone, medrisone, triamcinolone, hydrocortisone, prednicarbate, deflazacort, halometasone, thixocortol, prednilidine (21-diethyl-aminoacetate) , prednival, parametasone, methylprednisolone, meprednisone, mazipredone, isoflupredone, halopredone acetate, halcinonide, formocorthal, flurandrenolide, fluprednisolone, fluprednin acetate, fluperolone acetate, fluocortolone, butyl fluocortin, fluocinonide, fluocinolone acetonide, flunisolode, flumetasone, fludrocorstisone, enoxolone , difluprednate, diflucortolone, diflorasone diacetate, desoximetasone, desonido, cortivazol, corticosterone, cortisone, cloprednol, clocortolone, clobetasone, clobetasol, chloroprednisone, cafestol, budesonide, beclomethasone, amcinonide, alopregnano acetonide, alclometasone, 21-acetoxipregnenolone, tralonido, diflurasone acetate , desaci lcortivazole, budesonide, desacylcortivazole oxetanone and mixtures thereof.

33. The method of 32, where the glucocorticoid is betamethasone.

34. A pharmaceutical composition for the treatment of atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, allergies to food and medicines, allergic contact dermatitis, seborrheic dermatitis [sic], neurodermatitris, allergic asthma, allergic ocular manifestations such as conjunctivitis and iridocyclitis, allergic reactions to stings and insect bites , the composition contains: (i) a therapeutically effective amount of loratadine or a pharmaceutically acceptable salt or solvate thereof; (ii) a therapeutically effective amount of betamethasone; and (iii) lactose.

35. The composition of claim 34, additionally comprises magnesium stearate and croscarmellose sodium.

36. A method for the treatment of atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, allergies to food and medicines, allergic contact dermatitis, seborrheic dermatitis [sic], neurodermatitis, allergic asthma, allergic ocular manifestations such as conjunctivitis and iridocyclitis, Allergic reactions to stings and insect bites, in a mammalian organism in need of treatment, the method consists of administering to the organism a composition containing: (i) a therapeutically effective amount of loratadine or a pharmaceutically acceptable salt or solvate thereof; (ii) a therapeutically effective amount of betamethasone; and (iii) lactose.

37. The method of claim 36, wherein the composition additionally contains magnesium stearate and croscarmellose sodium.